Abstract: The invention relates a fluorescent compound of formula I: wherein A is selected from P, P?O and N; ·R1 is a residue comprising an oxygen atom·R2 is a residue comprising an oxygen atom, or a halogen, ·R3, R4 and R5 are alkyls, possibly substituted or a salt or a solvate thereof. The compound is useful as a fluorescent probe sensitive to membrane fluidity and for diagnosing cancer.

Abstract: Nanoparticles that can be used as hydrosilylation and dehydrogenative silylation catalysts. The nanoparticles have at least one transition metal with an oxidation state of 0, chosen from the metals of columns 8, 9 and 10 of the periodic table, and at least one carbonyl ligand, preferably a silicide.

Abstract: The present invention relates to a method for manufacturing a chromatography column, in particular for a gas phase chromatography, comprising a stationary phase made from a sol. This method comprises the following steps: (a) introducing this sol at the first end of the column, (b) moving said sol towards the second end of the column, so that a sol layer is formed on the internal wall of the column, this layer being able to form a gel on said internal wall, and (c) drying of the gel. The present invention also relates to a capillary column as well as to a microcolumn which may be manufactured according to this method.

Abstract: The present invention relates to a method for manufacturing a chromatography column, in particular for a gas phase chromatography, comprising a stationary phase made from a sol. This method comprises the following steps: (a) introducing this sol at the first end of the column, (b) moving said sol towards the second end of the column, so that a sol layer is formed on the internal wall of the column, this layer being able to form a gel on said internal wall, and (c) drying of the gel. The present invention also relates to a capillary column as well as to a microcolumn which may be manufactured according to this method.

Abstract: The present invention relates to novel pyrrolidine derivatives of formula (I): wherein R1, R2, R3, R4, R5 and X are as defined in claim 1, optionally in a zwitterionic form, in the form of a pure optical isomer, or in the form of a mixture of optical isomers in any proportions, or in a form enriched with an optical isomer, as well as their pharmaceutically acceptable salts, solvates or hydrates, and pharmaceutical compositions containing such compounds. These compounds are notably useful for treating, in particular in human beings, epilepsy, ischemia, neurodegenerative diseases such as Parkinson's disease or Huntington's chorea, multiple sclerosis, Devic's disease, Alzheimer's disease, psychiatric diseases such as schizophrenia, depression, addiction, allodynia and hyperalgia.

Abstract: The invention relates to a method for converting ethylene into propylene consisting in reacting said ethylene with a supported metal compound comprising an aluminium oxide based support to which a tungsten hydride is grafted. Said reaction is carried out at a temperature ranging from 20 to 600° C., preferably between 50 and 350° C., at an absolute pressure ranging from 0.01 to 8 MPa, preferably between 0.01 and 1 MPa. A catalyst is regeneratable by introducing hydrogen at a temperature of 50-300° C.

Abstract: The invention relates to a method for metathesis of one or several reagents comprising a linear or branched hydrocarbon chain containing a double olefinic bond Csp2?Csp2 consisting in reacting said reagent or reagents with a supported metal compound comprising an aluminum oxide-based support to which a tungsten hydride is grafted. Typically, each said reagent or reagents comprises from 2 to 30 carbon atoms. The reagent can be embodied in the form of olefin. The inventive method can be used, for example for producing propylene from ethylene and butane.

Abstract: A method for converting a polymer or oligomer derived from an ethylenically unsaturated monomer into alkanes or into a hydrocarbon fraction or a lower oligomer fraction by controlled hydrocracking, wherein the polymer or oligomer is exposed to a catalyst based on a metal hydride or an organometallic complex supported on a mineral carrier, the complex having at least one hydrocarbon ligand and optionally at least one hydride ligand, and the resulting mixture is reacted with hydrogen to cause catalytic hydrocracking of the polymer or oligomer. The polymer or oligomer is broken down into reclaimable products with a lower molecular weight for use, e.g., in the field of polymers, particularly controlled molecular weight polymers, fuels or lubricants.